Trials / Terminated
TerminatedNCT00646425
The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis
Randomized, Double-Masked, Placebo-controlled Evaluation of the Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis Who Undergo Tapering of Concomitant Immunosuppressive Medications
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Cerimon Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Basiliximab | 40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses |
| DRUG | Placebo | Placebo to match basiliximab |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-03-28
- Last updated
- 2010-08-19
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00646425. Inclusion in this directory is not an endorsement.